Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
100
Frequently Asked Questions
What is Market Cap of Stemline Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Stemline Therapeutics Inc market cap is $621.2M.
What is the 52-week high for Stemline Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Stemline Therapeutics Inc 52 week high is $18.22 as of September 10, 2025.
What is the 52-week low for Stemline Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Stemline Therapeutics Inc 52 week low is $3.21 as of September 10, 2025.
What is Stemline Therapeutics Inc stock price today?
Stemline Therapeutics Inc stock price today is $11.83.
What was Stemline Therapeutics Inc stock price yesterday?
Stemline Therapeutics Inc stock price yesterday was $12.00.
What is the PE ratio of Stemline Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Stemline Therapeutics Inc’s P/E ratio is None.
What is the Price-to-Book ratio of Stemline Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Stemline Therapeutics Inc P/B ratio is 4.2069.
What is Stemline Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Stemline Therapeutics Inc's EBITDA is -1.11.
What is the 50-day moving average of Stemline Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Stemline Therapeutics Inc 50-day moving average is $8.91.
How many employess does Stemline Therapeutics Inc has?
